Similar articles for PMID: 18370566

Year	Number of Results
2001	1
2002	2
2003	3
2004	2
2005	5
2006	14
2007	13
2008	17
2009	21
2010	14
2011	14
2012	12
2013	19
2014	19
2015	4
2016	6
2017	7
2018	5
2019	4
2020	8
2021	11
2022	25
2023	10
2024	0

1

Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.

Kreck S, Klaus J, Leidl R, von Tirpitz C, Konnopka A, Matschinger H, König HH. Kreck S, et al. Pharmacoeconomics. 2008;26(4):311-28. doi: 10.2165/00019053-200826040-00004. Pharmacoeconomics. 2008. PMID: 18370566

2

Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.

Ito K, Blinder VS, Elkin EB. Ito K, et al. J Clin Oncol. 2012 May 1;30(13):1468-75. doi: 10.1200/JCO.2011.38.7001. Epub 2012 Feb 27. J Clin Oncol. 2012. PMID: 22370313

3

The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.

Fleurence RL, Iglesias CP, Johnson JM. Fleurence RL, et al. Pharmacoeconomics. 2007;25(11):913-33. doi: 10.2165/00019053-200725110-00003. Pharmacoeconomics. 2007. PMID: 17960951 Review.

4

Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.

Parthan A, Kruse M, Agodoa I, Silverman S, Orwoll E. Parthan A, et al. Bone. 2014 Feb;59:105-13. doi: 10.1016/j.bone.2013.11.002. Epub 2013 Nov 12. Bone. 2014. PMID: 24231131

5

Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.

Jansen JP, Gaugris S, Bergman G, Sen SS. Jansen JP, et al. Curr Med Res Opin. 2008 Mar;24(3):671-84. doi: 10.1185/030079908X260998. Epub 2008 Jan 24. Curr Med Res Opin. 2008. PMID: 18221588

6

Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.

Tosteson AN, Burge RT, Marshall DA, Lindsay R. Tosteson AN, et al. Am J Manag Care. 2008 Sep;14(9):605-15. Am J Manag Care. 2008. PMID: 18778176 Free article.

7

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J. Stevenson M, et al. Health Technol Assess. 2005 Jun;9(22):1-160. doi: 10.3310/hta9220. Health Technol Assess. 2005. PMID: 15929857 Free article. Review.

8

Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.

Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D. Parthan A, et al. Appl Health Econ Health Policy. 2013 Oct;11(5):485-97. doi: 10.1007/s40258-013-0047-8. Appl Health Econ Health Policy. 2013. PMID: 23868102

9

A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.

Davis S, Martyn-St James M, Sanderson J, Stevens J, Goka E, Rawdin A, Sadler S, Wong R, Campbell F, Stevenson M, Strong M, Selby P, Gittoes N. Davis S, et al. Health Technol Assess. 2016 Oct;20(78):1-406. doi: 10.3310/hta20780. Health Technol Assess. 2016. PMID: 27801641 Free PMC article. Review.

10

Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.

Hiligsmann M, Reginster JY. Hiligsmann M, et al. Pharmacoeconomics. 2011 Oct;29(10):895-911. doi: 10.2165/11539980-000000000-00000. Pharmacoeconomics. 2011. PMID: 21692551 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

200 results

Results by year